CD8A and neoplasm: The antitumor immunity mediated by CD8+ T cell was responsible for the potent anticancer activity of DOX@3D-MPs, as evidenced by the abrogation of DOX@3D-MPs-induced antitumor therapeutic efficacy in immunocompetent mouse models after CD8+ T cell depletion using anti-CD8 antibody and in the nude mouse tumor models.